Pegylated liposomal doxorubicin (Lipo-Dox®) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long-term follow-up

Gynecologic Oncology

Volumn 101, Issue 3, 2006, Pages 423-428

  Chou, Hung Hsueh ^a   Wang, Kung Liahng ^b   Chen, Chi An ^c   Wei, Lin Hung ^c   Lai, Chyong Huey ^a   Hsieh, Chang Yao ^c   Yang, Yuh Cheng ^b   Twu, Nae Fang ^d   Chang, Ting Chang ^a   Yen, Ming Shyen ^d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Pegylated liposomal doxorubicin; Recurrent ovarian carcinoma; Salvage therapy

Indexed keywords

CA 125 ANTIGEN; DOXORUBICIN; PLATINUM;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GYNECOLOGY; HUMAN; LEUKOPENIA; LONG TERM CARE; MULTICENTER STUDY; NAUSEA AND VOMITING; ONCOLOGY; OVARY CARCINOMA; PRIORITY JOURNAL; SKIN MANIFESTATION; SKIN PIGMENTATION; TAIWAN; THROMBOCYTOPENIA; TIME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 33646559501     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.10.027     Document Type: Article

References (25)

1. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
2. Shapiro J.D., Millward M.J., Rischin D., et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63 (1996) 89-93
3. Bookman M.A., Malmstrom H., Bolis G., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16 (1998) 3345-3352
4. Rose P.G., Blessing J.A., Mayer A.R., and Homesley H.D. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 16 (1998) 405-410
5. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J. Clin. Oncol. 9 (1991) 1668-1674
6. A'Hern R.P., and Gore M.E. Impact of doxorubicin on survival in advanced ovarian cancer. J. Clin. Oncol. 13 (1995) 726-732
7. Fanning J., Bennett T.Z., and Hilgers R.D. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet. Gynecol. 80 (1992) 954-960
8. Williams C.J., Stewart L., Parmar M., and Guthrie D. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group. Semin. Oncol. 19 (1992) 120-128
9. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339 (1998) 900-905
10. Gokhale P.C., Radhakrishnan B., Husain S.R., et al. An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation. Br. J. Cancer 74 (1996) 43-48
11. Herman E.H., Rahman A., Ferrans V.J., Vick J.A., and Schein P.S. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 43 (1983) 5427-5432
12. Harashima H., Midori Y., Ohshima S., Yachi K., Kikuchi H., and Kiwada H. Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats (II). Biopharm. Drug Dispos. 14 (1993) 595-608
13. Papahadjopoulos D., Allen T.M., Gabizon A., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 11460-11464
14. Gabizon A., Meshorer A., and Barenholz Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl. Cancer Inst. 77 (1986) 459-469
15. Gabizon A., Catane R., Uziely B., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54 (1994) 987-992
16. Rahman A., Treat J., Roh J.K., et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J. Clin. Oncol. 8 (1990) 1093-1100
17. Huang S.K., Lee K.D., Hong K., Friend D.S., and Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52 (1992) 5135-5143
18. Rustin G.J., Nelstrop A.E., McClean P., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14 (1996) 1545-1551
19. Thigpen J.T., Vance R.B., and Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 71 (1993) 1559-1564
20. Markman M., Hall J., Spitz D., et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J. Clin. Oncol. 20 (2002) 2365-2369
21. Gabizon A., and Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 6949-6953
22. Muggia F.M., Hainsworth J.D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15 (1997) 987-993
23. Safra T., Groshen S., Jeffers S., et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer 91 (2001) 90-100
24. Gordon A.N., Granai C.O., Rose P.G., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. 18 (2000) 3093-3100
25. Markman M., Kennedy A., Webster K., Peterson G., Kulp B., and Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol. 78 (2000) 369-372